Cargando…

Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus–A randomized, placebo-controlled cross-over study

PURPOSE: Results from large scale cardiovascular outcome trials in patients with type 2 diabetes mellitus (DM2) have found that sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce cardiovascular death and hospitalization for heart failure, but the mechanisms behind the beneficial cardiovascula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suhrs, Hannah Elena, Nilsson, Malin, Bové, Kira Bang, Zander, Mette, Prescott, Eva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836314/ https://www.ncbi.nlm.nih.gov/pubmed/35148357 http://dx.doi.org/10.1371/journal.pone.0263481

Ejemplares similares

The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults
por: Nilsson, Malin, et al.
Publicado: (2019)

Comprehensive treatment of microvascular angina in overweight women – a randomized controlled pilot trial
por: Bove, Kira Bang, et al.
Publicado: (2020)

Pro-inflammatory biomarkers in women with non-obstructive angina pectoris and coronary microvascular dysfunction
por: Schroder, Jakob, et al.
Publicado: (2019)

Effect of ACE-inhibition on coronary microvascular function and symptoms in normotensive women with microvascular angina: A randomized placebo-controlled trial
por: Michelsen, Marie Mide, et al.
Publicado: (2018)

Inflammation, non-endothelial dependent coronary microvascular function and diastolic function—Are they linked?
por: Suhrs, Hannah E., et al.
Publicado: (2020)

Impaired coronary flow velocity reserve is associated with cardiovascular risk factors but not with angina symptoms
por: Bove, Kira Bang, et al.
Publicado: (2021)

Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes – a randomized, single-blinded, cross-over pilot study
por: Faber, Rebekka, et al.
Publicado: (2015)

Empagliflozin inhibits coronary microvascular dysfunction and reduces cardiac pericyte loss in db/db mice
por: Tu, Yimin, et al.
Publicado: (2022)

Doppler Echocardiography Assessment of Coronary Microvascular Function in Patients With Angina and No Obstructive Coronary Artery Disease
por: Schroder, Jakob, et al.
Publicado: (2021)

Coronary microvascular dysfunction in diabetes mellitus
por: Kibel, Aleksandar, et al.
Publicado: (2017)

SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob(−/−) mice
por: Adingupu, Damilola D., et al.
Publicado: (2019)

Empagliflozin and Protecting Microvascular Support of Heart Mechanics: SGLT2 Inhibition or More?
por: Mantsounga, Chris Sorel, et al.
Publicado: (2019)

Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin
por: Juni, Rio P., et al.
Publicado: (2019)

Differential Effects of Empagliflozin on Microvascular Complications in Murine Models of Type 1 and Type 2 Diabetes
por: Eid, Stephanie A., et al.
Publicado: (2020)

Bimodal Pattern of Coronary Microvascular Involvement in Diabetes Mellitus
por: Sezer, Murat, et al.
Publicado: (2016)

Bimodal Pattern of Coronary Microvascular Involvement in Diabetes Mellitus
Publicado: (2017)

Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus
por: Hoshika, Yu, et al.
Publicado: (2021)

Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure
por: Packer, Milton, et al.
Publicado: (2023)

Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis
por: Zou, Rongjun, et al.
Publicado: (2022)

Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale
por: Kubota, Yoshiaki, et al.
Publicado: (2018)

Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission
por: Zhou, Hao, et al.
Publicado: (2017)

Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Options for empagliflozin in combination therapy in type 2 diabetes mellitus
por: Hershon, Kenneth S
Publicado: (2016)

Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
por: Shimizu, Wataru, et al.
Publicado: (2020)

Coronary microvascular function, insulin sensitivity and body composition in predicting exercise capacity in overweight patients with coronary artery disease
por: Jürs, Anders, et al.
Publicado: (2015)

The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial
por: Gohari, Sepehr, et al.
Publicado: (2022)

Efficacy and Safety of Empagliflozin in the Management of Diabetes Mellitus in Heart Transplant Recipients
por: Cehic, Matthew G., et al.
Publicado: (2019)

Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
por: Anderson, John E., et al.
Publicado: (2016)

Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus
por: Albugami, Muneerah M., et al.
Publicado: (2020)

Fournier’s Gangrene in an HIV-Positive Patient on Empagliflozin for the Treatment of Diabetes Mellitus
por: Khokhar, Farzam, et al.
Publicado: (2022)

Efficacy and safety of empagliflozin for type 2 diabetes mellitus: Meta-analysis of randomized controlled trials
por: Zhang, Yun-Jing, et al.
Publicado: (2018)

Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options
por: Salvatore, Teresa, et al.
Publicado: (2022)

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
por: Ahmann, Andrew
Publicado: (2015)

Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
por: Levine, Matthew J.
Publicado: (2017)

Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
por: Kinduryte Schorling, Ona, et al.
Publicado: (2020)

Microvascular Dysfunction in Patients With Type II Diabetes Mellitus: Invasive Assessment of Absolute Coronary Blood Flow and Microvascular Resistance Reserve
por: Gallinoro, Emanuele, et al.
Publicado: (2021)

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
por: Zinman, Bernard, et al.
Publicado: (2014)

Study rationale and design of a study of EMPAgliflozin’s effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial
por: Gohari, Sepehr, et al.
Publicado: (2021)

Coronary Microvascular Dysfunction
por: Vancheri, Federico, et al.
Publicado: (2020)

Coronary Microvascular Disease
por: Thakker, Ravi A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l797e1e9ork1ip50cdi7jgeqd3